The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Under JFC, the company initially closed more stores than it opened. It started from 1,189 stores upon buying it to just 1,048 in 2021. However, the number of stores has risen again to 1,232 as of 2024.
==== Other drugs ==== Istradefylline (KW-6002; Nourianz; Nouriast) – adenosine A2A receptor antagonist [347] Pimavanserin (ACP-103; BVF-048; Nuplazid) – serotonin 5-HT2A receptor antagonist – Parkinson's disease psychosis [348]
DBNPA dust may cause mechanical (abrasive) irritation to the skin, eyes and respiratory system and is severely irritating to the eyes and may cause permanent corneal damage. Skin contact may cause an allergic skin reaction. Pre-existing skin disorders may even be aggravated by over-exposure to this product. Regarding long-term health effects, DBNPA contains material that may cause target organ damage, based on animal data. Repeated or prolonged inhalation of DBPNA dust can lead to chronic respiratory problems. Once sensitized, an allergic skin reaction may occur when subsequently exposed to very low levels of DBNPA.
Sources: en.wikipedia.org
=== Competition binding === Competitive binding experiments aim to determine the binding of a labeled radioligand at one specific concentration while subjected to various concentrations of a competitor, usually an unlabeled ligand. There are many purposes to competitive binding experiments, including being able to validate that the radioligand of interest will bind to the receptor with the expected affinity and potency even in the presence of a competitor. This experiment would also help determine if the radioligand will be able to recognize and bind to the correct receptor. Competitive binding experiments also serve to study the binding ability of a low-affinity drug, as it can be used as an unlabeled competitor. Receptor number and affinity can also be determined through this experiment.
=== Cancer === Based on cell growth experiments, animal cancer models, and epidemiological studies, it appears that IGFBP-3 functions as a low-penetrance tumor suppressor gene. Dysregulation of IGFBP-3 has been implicated in many cancers. Downregulation of its tissue expression by promoter hypermethylation in some cancers, such as hepatoma and non-small cell lung cancer may be associated with poor patient outcome. However, consistent with the dual inhibitory and stimulatory roles of IGFBP-3 seen in cell culture, there are other cancer types, such as breast cancer, pancreatic cancer, and clear cell renal cell cancer in which high tissue IGFBP-3 expression has been linked to poor prognostic features or patient outcome. The mechanisms regulating these contrasting effects of IGFBP-3 in vivo are not well understood. Since IGFBP-3 is abundant in the bloodstream of healthy adults (typically 2–4 mg/L), and is largely stabilized by its complex formation with IGFs and ALS, it is unlikely that tumor-derived IGFBP-3 has a large influence on circulating levels. There have been many studies linking circulating IGFBP-3 levels to the presence, or risk, of various cancers, or to patient outcomes. but unequivocal conclusions have often been lacking. For example, high plasma IGFBP-3 levels were associated with a reduced prospective risk of colorectal cancer in women. but in a study including men and women, colon cancer risk was positively associated with plasma IGFBP-3, while there was no significant association for rectal cancer.
After missing the first two matches of the 2014 season through suspension, Melksham played his first match of the year in the eighty-one point win against Carlton at the Melbourne Cricket Ground in round three. Playing a role in both the midfield and the back-line, Melksham played every match up to the sixty-four-point win against Collingwood at the Melbourne Cricket Ground in round seventeen; a drop in form throughout the year saw Melksham dropped for the round eighteen match against the Western Bulldogs at Etihad Stadium. After playing one match in the VFL, he returned for the eighteen point loss against Richmond at the Melbourne Cricket Ground in round twenty, and played the next week in the three-point win against West Coast at Etihad Stadium where he was substituted out of the match during the third quarter. He was omitted the next week for the match against Gold Coast at Etihad Stadium and missed the remainder of the year to finish with sixteen matches in total. Melksham played the first thirteen matches of the 2015 season, including his 100th AFL match in round four in the Anzac Day clash against Collingwood at the Melbourne Cricket Ground, before missing the round fifteen match against Melbourne at the Melbourne Cricket Ground due to a hamstring injury sustained at training.
Sources: en.wikipedia.org
Flareups continued to occur starting on June 19, sending more smoke into the air which continued to impact the local Boyle Heights community. The warehouse also experienced severe structural damage during the fire. The solar panels on the roof and the collapse of roof structure made fighting the fire difficult. On June 18, the shelter-in-place order was briefly reinstated after crews detected hydrogen fluoride, indicating that a lithium-ion battery (likely from a battery-operated forklift) had ignited inside the facility. Officials also raised concerns that the estimated 85 million pounds of frozen food (including bread, poultry, pork, and beef) inside the facility—no longer kept cold by the damaged refrigeration system—would begin to decompose, creating foul odors and potential biohazards, which Mayor Bass compared to food spoiling during a prolonged power outage. Health concerns intensified as the fire continued, with officials extending particulate matter advisories and Los Angeles Unified School District relocating students from several nearby schools due to air quality impacts. Regulatory monitors and sensors recorded improved PM2.5 levels in Central and Southeast Los Angeles, the San Gabriel Valley, and the San Fernando Valley, though air quality near the fire itself remained elevated, with "Very Unhealthy" conditions measured throughout the day in Boyle Heights; other areas ranged from "Good" to "Moderate" for PM2.5.
The first three prize winners at the late coursing meeting at Great Bend were trained on Spratt's Patent Dog Biscuit. This same dog food won no less than three awards, including a gold medal, at the Exposition in Paris which has just closed. It would seem that the decision of the judges is more than backed up by the result in the kennel. Another good dog food is that manufactured by Austin & Graves, of Boston. They, too, seem to be meeting with great success in their line. Canned horse meat was introduced in the United States under the Ken-L Ration brand after World War I as a means to dispose of excess horses no longer needed for the war. The 1930s saw the introduction of canned cat food and dry meat-meal dog food by the Gaines Food Co. By the time World War II ended, pet food sales had reached $200 million. In the 1950s Spratt's became part of General Mills. For companies such as Nabisco, Quaker Oats, and General Foods, pet food represented an opportunity to market by-products as a profitable source of income.
Natural freshwater diatomaceous earth is preferred by many researchers over chromic oxide, which has been widely used for the same purpose, the latter being a known carcinogen and, therefore, a potential hazard to research personnel.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.